Immutep Ltd has released a press release.
Immutep announces improving data from TACTI-002 ph II trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Immutep receives $3.6M R&D French tax incentive
- Immutep granted Japanese patent for eftilagimod alpha
- INSIGHT-004 and TACTI-002 data to be presented at ASCO
- Immutep Investor Presentation
- Immutep Reports Positive Phase II TACTI-002 Data
Later from Immutep
- Immutep receives A$1,437,826 R&D Tax Incentive
- Immutep Completes Recruitment for Part A of TACTI-002 trial
- US patent granted for IMP701 antibody
- Immutep granted US patent for eftilagimod alpha
- Recruitment of stage 1 of part B in TACTI-002 study complete
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep